To examine if A1AR might regulate tau pathology, we first treated primary neurons with an adenosine receptor agonist (adenosine) or antagonist (caffeine), followed by treating with AD-tau seeds and subsequent measurement of induced mouse tau aggregates using a mouse tau-specific antibody (R2295M) (Fig. S12a). Here, MAPT is linked to Alzheimer disease.